9-ING-41 [CAS 1034895-42-5]

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].

[1034895-42-5]

C22H13FN2O5

404.35

O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O

Apoptosis; Autophagy; GSK-3

GSK-3β

99.13

DMSO : 50 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H301, H311, H331, H341

H301, H311, H331, H341